Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 130, Issue 15
October 12 2017
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Racial/ethnic disparities: need more work!
Clinical Trials & Observations
Ola Landgren
View Articletitled, Racial/ethnic disparities: need more work!
INSIDE BLOOD COMMENTARY
RUNX1 in T-ALL: tumor suppressive or oncogenic?
Takaomi Sanda
View Articletitled, RUNX1 in T-ALL: tumor suppressive or oncogenic?
INSIDE BLOOD COMMENTARY
Twins actin’ differently
Renhao Li
View Articletitled, Twins actin’ differently
INSIDE BLOOD COMMENTARY
Impacting inhibitor development in hemophilia A
Barbara A. Konkle
View Articletitled, Impacting inhibitor development in hemophilia A
INSIDE BLOOD COMMENTARY
Vorinostat is victorious in GVHD prevention
Shernan G. Holtan,Daniel J. Weisdorf
View Articletitled, Vorinostat is victorious in GVHD prevention

BLOOD SPOTLIGHT

Inflammation: a key regulator of hematopoietic stem cell fate in health and disease
Eric M. Pietras
View Articletitled, Inflammation: a key regulator of hematopoietic stem cell fate in health and disease

REVIEW ARTICLE

Racial and ethnic disparities in hematologic malignancies
Clinical Trials & Observations
Kedar Kirtane,Stephanie J. Lee
View Articletitled, Racial and ethnic disparities in hematologic malignancies

CLINICAL TRIALS AND OBSERVATIONS

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Clinical Trials & Observations
Ammar Majeed,Anna Ågren,Margareta Holmström,Maria Bruzelius,Roza Chaireti,Jacob Odeberg,Eva-Lotta Hempel,Maria Magnusson,Tony Frisk,Sam Schulman
View Articletitled, Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Clinical Trials & Observations
Sébastien Anguille,Ann L. Van de Velde,Evelien L. Smits,Viggo F. Van Tendeloo,Gunnar Juliusson,Nathalie Cools,Griet Nijs,Barbara Stein,Eva Lion,Ann Van Driessche,Irma Vandenbosch,Anke Verlinden,Alain P. Gadisseur,Wilfried A. Schroyens,Ludo Muylle,Katrien Vermeulen,Marie-Berthe Maes,Kathleen Deiteren,Ronald Malfait,Emma Gostick,Martin Lammens,Marie M. Couttenye,Philippe Jorens,Herman Goossens,David A. Price,Kristin Ladell,Yoshihiro Oka,Fumihiro Fujiki,Yusuke Oji,Haruo Sugiyama,Zwi N. Berneman
View Articletitled, Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Supplemental data

LYMPHOID NEOPLASIA

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia
AHyun Choi,Anuradha Illendula,John A. Pulikkan,Justine E. Roderick,Jessica Tesell,Jun Yu,Nicole Hermance,Lihua Julie Zhu,Lucio H. Castilla,John H. Bushweller,Michelle A. Kelliher
View Articletitled, RUNX1 is required for oncogenic <em>Myb</em> and <em>Myc</em> enhancer activity in T-cell acute lymphoblastic leukemia
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

NOX5 and p22phox are 2 novel regulators of human monocytic differentiation into dendritic cells
Viviana Marzaioli,Margarita Hurtado-Nedelec,Coralie Pintard,Asma Tlili,Jean-Claude Marie,Renato C. Monteiro,Marie-Anne Gougerot-Pocidalo,Pham My-Chan Dang,Jamel El-Benna
View Articletitled, NOX5 and p22phox are 2 novel regulators of human monocytic differentiation into dendritic cells
Supplemental data

PLATELETS AND THROMBOPOIESIS

Twinfilin 2a regulates platelet reactivity and turnover in mice
Simon Stritt,Sarah Beck,Isabelle C. Becker,Timo Vögtle,Markku Hakala,Katrin G. Heinze,Xiaoping Du,Markus Bender,Attila Braun,Pekka Lappalainen,Bernhard Nieswandt
View Articletitled, Twinfilin 2a regulates platelet reactivity and turnover in mice
Supplemental data

THROMBOSIS AND HEMOSTASIS

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
Clinical Trials & Observations Brief Report
Frits R. Rosendaal,Roberta Palla,Isabella Garagiola,Pier M. Mannucci,Flora Peyvandi,for the SIPPET Study Group,for the SIPPET Study Group,for the SIPPET Study Group,for the SIPPET Study Group,for the SIPPET Study Group
View Articletitled, Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
Supplemental data

TRANSPLANTATION

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
Clinical Trials & Observations
Sung Won Choi,Thomas Braun,Israel Henig,Erin Gatza,John Magenau,Brian Parkin,Attaphol Pawarode,Mary Riwes,Greg Yanik,Charles A. Dinarello,Pavan Reddy
View Articletitled, Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

LETTERS TO BLOOD

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
Clinical Trials & Observations
Srdan Verstovsek,Francesco Passamonti,Alessandro Rambaldi,Giovanni Barosi,Elisa Rumi,Elisabetta Gattoni,Lisa Pieri,Huiling Zhen,Muriel Granier,Albert Assad,Mario Cazzola,Hagop M. Kantarjian,Tiziano Barbui,Alessandro M. Vannucchi
View Articletitled, Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
Supplemental data
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Clinical Trials & Observations
Antonio Salar,Eva Domingo-Domenech,Carlos Panizo,Concepción Nicolás,Joan Bargay,Ana Muntañola,Miguel Canales,José Luis Bello,Juan Manuel Sancho,José Francisco Tomás,María José Rodríguez,Javier Peñalver,Carlos Grande,José Javier Sánchez-Blanco,Luis Palomera,Reyes Arranz,Eulogio Conde,Mar García,Juan Fernando García,Dolores Caballero,Carlos Montalbán
View Articletitled, Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

BLOOD WORK

AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis
Zhaodong Xu
View Articletitled, AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis
All Issues

Advertisement intended for health care professionals

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads
Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals